Tien Laboratory

Researcher holding a bottle of liquid in the lab


We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.

Prinicipal Investigator

Lab Members

YuWei Chang hexagon cutoutRead Bio

YuWei Chang, PhDPostdoctoral Fellow

Chelsea Pennington-Krygier hexagon cutoutRead Bio

Chelsea Pennington-KrygierCLIA Lab Manager, Research Tech

Anita DeSantis hexagon cutoutRead Bio

Anita DeSantisResearch Technician

Current and Published Research

  • An-Chi Tien, Jing Li, Xun Bao, Alanna DeRogatis, Seongho Kim, Shwetal Mehta and Nader Sanai (2019) A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clinical Cancer Research (in press).
  • Amelie Griveau, Giorgio Seano, Samuel J Shelton, Arman Jahangiri, Kirsten Obernier, Olle R Lindberg, Robert Kupp, Itay Tirosh, Tracy J Yuen, An-Chi Tien, Jennifer K Sabo, Nancy Wang, Shanmugarajan Krishnan, Jonas Kloepper, Louis Larrouquere, Emmanuelle Huillard, Michael C Oldham, Anders I Persson, William A Weiss, Tracy T Batchelor, Anat Stemmer-Rachamimov, Arturo Alvarez-Buylla, Joanna J Phillips, Manish Aghi, Mario L Suva, Shwetal Mehta, Rakesh K Jain and David H Rowitch (2018) A glial signature and Wnt7 signaling regulates glioma-vascular interactions and tumor microenvironment Cancer Cell 33, 874-8.
  • Jing Zhou*, An-Chi Tien*, John A Alberta, Scott B Ficarro, Amelie Griveau, Yu Sun, Janhavee S Deshpande, Joseph D Card, Meghan Morgan-Smith, Wojciech Michowski, Rintaro Hashizume, C David James, Keith L Ligon, William D Snider, Peter Sicinski, Jarrod A Marto, David H Rowitch, Charles D Stiles (2017) A sequentially priming phosphorylation cascade activates the gliomagenic transcription factor Olig2 Cell Reports 18, 3167-77 (* Equal contribution)
  • Robert Kupp, Lior Shtayer, An-Chi Tien, Emily Szeto, Nader Sanai, Daveid H. Rowitch, Shwetal Mehta (2016) Lineage-restricted Olig2-RTK signaling governs the molecular subtype of glioma stem-like cells Cell Reports 16, 2838-45
  • Hui-Hsin Tsai, Roeben Munji, Dimitrios Davalos, An-Chi Tien, Calvin Kuo, Jonah R. Chan, Richard Daneman, Stephen P.J. Fancy (2016) Oligodendrocyte precursors migrate along vasculature in the developing nervous system. Science 351, 379-84
  • Shi-Bing Yang, An-Chi Tien, Gayatri Boddupalli, Allison W. Xu, Yuh Nung Jan, Lily Yeh Jan (2012) Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 75, 425-36
  • An-Chi Tien*, Hui-Hsin Tsai*, Anna Molofsky, Martin McMahon, Lynette Foo, Aparna Kaul, David H. Gutmann, Ben A. Barres and David H. Rowitch (2012) Temporal-spatial regulation of astrocyte precursor cell proliferation by BRAF signaling in mammalian spinal cord. Development 139, 2477-87 (* Equal contribution)
  • Yu Sun, Dimphna H. Meijer, John A. Alberta, Shwetal Mehta, Michael F. Kane, An-Chi Tien, Hui Fu, Magdalena A. Petryniak, Gregory B. Potter, Zijing Liu, James F. Powers, I. Sophie Runquist, David H. Rowitch, Charles D. Stiles (2011) Phosphorylation state of Olig2 regulates proliferation of neural progenitor. Neuron 69, 906-17